Finasteride vs HCG
FDA Approved vs FDA Approved
monitor Mechanism-based · 60% Both Finasteride and HCG can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed.
Molecular Data
Finasteride HCG
Weight 372.54 Da 36,700 Da
Half-life 6-8 hours (DHT suppression persists ~24 hours) 24-36 hours
Chain — 237 amino acids (alpha: 92, beta: 145)
Type Synthetic 4-azasteroid compound Heterodimeric glycoprotein
Key Benefits
Finasteride
01 Reduces scalp DHT by approximately 66% at 1mg daily
02 Slows or stops hair loss progression in roughly 90% of men
03 Produces visible hair regrowth in approximately 48% of men within 1-2 years
04 FDA-approved with over 25 years of clinical use and long-term safety data
05 Convenient once-daily oral dosing with no injections required
06 Well-characterized side effect profile with low incidence of adverse events
07 Can be combined with minoxidil for enhanced efficacy
HCG
01 Maintains testicular function during TRT
02 Preserves fertility and prevents testicular atrophy
03 Stimulates endogenous testosterone production
04 Induces ovulation in women
05 FDA-approved for multiple indications
06 Well-established safety profile
Dosing Protocols
Finasteride
1mg/day (hair loss) or 5mg/day (BPH) / Once daily
HCG
250-1500 IU (lower for TRT adjunct, higher for fertility) / 2-3 times weekly, or every other day for lower doses
TRT Adjunct (Low) 250-500 IU Every other day
TRT Adjunct (Standard) 500-1000 IU Twice weekly
HCG Monotherapy 1500-2000 IU 2-3x weekly
Fertility (with FSH) 1500-2000 IU 2-3x weekly
Cryptorchidism (Pediatric) 1000-5000 IU 2-3x weekly for 3-4 weeks
Ovulation Trigger (Female) 5000-10,000 IU Single dose
PCT Protocol 1000-1500 IU Every other day for 2-3 weeks
Side Effects
Finasteride
Decreased libido (reported in 1.8% of men in clinical trials vs 1.3% placebo)
Erectile dysfunction (reported in 1.3% vs 0.7% placebo)
Decreased ejaculate volume (reported in 0.8% vs 0.4% placebo)
HCG
Gynecomastia (breast tenderness/swelling) due to increased estrogen
Headaches, irritability, and mood swings (especially initially)
Fluid retention and edema
Potential antibody formation with long-term use
Contraindications
Women who are pregnant or may become pregnant (finasteride is teratogenic and can cause abnormalities of external genitalia in a male fetus; even handling crushed tablets poses a risk)
Women who are breastfeeding
Known hypersensitivity to finasteride or any component of the formulation
Severe hepatic impairment (finasteride is metabolized by the liver)
Pediatric patients (not indicated for use in children)
Hormone-sensitive cancers (prostate, breast)
Pregnancy (except as prescribed)
Precocious puberty risk in children
Research Evidence
Finasteride HCG
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest — 2024
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.